Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 66

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 66
---
-line 
 therapy;                                                                                          |

| ● | the                                                                                  
 product’s convenience and ease of administration compared to alternative treatments; |

| ● | the                                                                                      
 willingness of the target patient population to try, and of physicians to prescribe, the 
 product;                                                                                 |

| ● | limitations                                                                        
 or warnings, including distribution or use restrictions contained in the product’s 
 approved labeling;                                                                 |

| ● | the                                                      
 approval of other new products for the same indications; |

| ● | changes                                                                   
 in the standard of care for the targeted indications for the product; and |

| ● | availability                                                                                  
 and amount of coverage and reimbursement from government payors, managed care plans and other 
 third-party payors.                                                                           |

Our future growth depends on our ability to successfully commercialize Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, Celgosivir and our other product candidates, and we can provide no assurance that we will successfully commercialize Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, Celgosivir and other product candidates. Our future growth depends on our ability to successfully commercialize Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, Celgosivir and our other product candidates, including our ability to:

| ● | conduct                                                                                        
 additional clinical trials and develop and obtain regulatory approval for Arakoda, Tafenoquine 
 (Arakoda or other regimen) for non-malaria prevention indications, Celgosivir or other product 
 candidates;                                                                                    |

| ● | successfully                                                                                     
 partner a companion genetic test (if required by the FDA) with the commercialization of Arakoda, 
 Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications and Celgosivir;    |

| ● | pursue                                                                                      
 additional indications for Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria  
 prevention indications and Celgosivir and develop other product candidates, including other 
 therapies; and                                                                              |

| ● | obtain                                                                                       
 commercial quantities of Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria     
 prevention indications and Celgosivir or other product candidates at acceptable cost levels. |

Any one of these or other factors could affect our ability to successfully commercialize products. If approved by the FDA, Taf